IRLAB receives positive feedback from EMA confirming alignment with FDA on Phase III program for Mesdopetam

Gothenburg, Sweden, 20 February, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company discovering and developing novel treatments for Parkinson’s disease, today announces that the European Medicines Agency (EMA) has provided positive feedback on the company’s proposed design for the Phase III program of mesdopetam. Based on EMA’s guidance, IRLAB can now proceed with preparations for the registration studies of the drug candidate, which has demonstrated efficacy in a phase Ib and in two Phase II studies against levodopa-induced dyskinesia in patients with Parkinson’s disease.

IRLAB strengthens its value creation capabilities through extended and expanded debt financing

IRLAB publishes full-year report for 2024